Oxymatrine suppresses proliferation and facilitates apoptosis of human ovarian cancer cells through upregulating microRNA-29b and downregulating matrix metalloproteinase-2 expression

Molecular Medicine Reports

Volumn 12, Issue 4, 2015, Pages 5369-5374

  Li, Jingwei ^a   Jiang, Kailei ^a   Zhao, Fujie ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Matrix metalloproteinase 2; microRNA 29b; Ovarian cancer; OVCAR 3 cells; Oxymatrine

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; GELATINASE A; MICRORNA 29B; OXYMATRINE; ALKALOID; MICRORNA; MIRN29 MICRORNA, HUMAN; QUINOLIZINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARIAN CANCER CELL LINE; PRECURSOR; PROTEIN EXPRESSION; UPREGULATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY TUMOR; RNA INTERFERENCE; TUMOR CELL LINE;

ALKALOIDS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MICRORNAS; OVARIAN NEOPLASMS; QUINOLIZINES; RNA INTERFERENCE;

EID: 84940554633     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3977     Document Type: Article

References (31)

1. Kim SI, Kim HS, Kim TH, Suh DH, Kim K, No JH, Chung HH, Kim YB and Song YS: Impact of underweight after treatment on prognosis of advanced-stage ovarian cancer. J Immunol Res 2014: 349546, 2014.
2. Barber A, Zhang T and Sentman CL: Correction: immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J Immunol 193: 1513, 2014.
3. Muralidhar GG and Barbolina MV: Chemokine receptors in epithelial ovarian cancer. Int J Mol Sci 15: 361-376, 2013.
4. Shen CC, Kang YH, Zhao M, He Y, Cui DD, Fu YY, Yang LL and Gou LT: WNT16B from ovarian fbroblasts induces differentiation of regulatory T cells through β-catenin signal in dendritic cells. Int J Mol Sci 15: 12928-12939, 2014.
5. Liu J, Li J, Zhang JF and Xin XY: Combination of fenretinide and selenite inhibits proliferation and induces apoptosis in ovarian cancer cells. Int J Mol Sci 14: 21790-21804, 2013.
6. Ekinci T, Ozbay PO, Yigit S, Yavuzcan A, Uysal S and Soylu F: The correlation between immunohistochemical expression of MMP-2 and the prognosis of epithelial ovarian cancer. Ginekol Pol 85: 121-130, 2014.
7. Grelewski PG and Bar JK: The role of p53 protein and MMP-2 tumor/stromal cells expression on progressive growth of ovarian neoplasms. Cancer Invest 31: 472-479, 2013.
8. Su Y, Gao L, Teng L, Wang Y, Cui J, Peng S and Fu S: Id1 enhances human ovarian cancer endothelial progenitor cell angiogenesis via PI3K/Akt and NF-κB/MMP-2 signaling pathways. J Transl Med 11: 132, 2013.
9. Laios A, Mohamed BM, Kelly L, Flavin R, Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, et al: Pre-treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screening. Int J Mol Sci 14: 2085-2103, 2013.
10. Wu DW, Hsu NY, Wang YC, Lee MC, Cheng YW, Chen CY and Lee H: c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT. Oncogene 34: 2072-2082, 2015.
11. Parpart S, Roessler S, Dong F, Rao V, Takai A, Ji J, Qin LX, Ye QH, Jia HL, Tang ZY, et al: Modulation of miR-29 expression by α-fetoprotein is linked to the hepatocellular carcinoma epigenome. Hepatology 60: 872-883, 2014.
12. Wu Z, Huang X, Huang X, Zou Q and Guo Y: The inhibitory role of Mir-29 in growth of breast cancer cells. J Exp Clin Cancer Res 32: 98, 2013.
13. Tan M, Wu J and Cai Y: Suppression of Wnt signaling by the miR-29 family is mediated by demethylation of WIF-1 in non-small-cell lung cancer. Biochem Biophys Res Commun 438: 673-679, 2013.
14. Wang C, Bian Z, Wei D and Zhang JG: miR-29b regulates migration of human breast cancer cells. Mol Cell Biochem 352: 197-207, 2011.
15. Yu PN, Yan MD, Lai HC, Huang RL, Chou YC, Lin WC, Yeh LT and Lin YW: Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int J Cancer 134: 542-551, 2014.
16. Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, Du Y, Zhang Y, Larsson E, Sheridan R, et al: Integrated analyses of microRNAs demonstrate their widespread Influence on gene expression in high-grade serous ovarian carcinoma. PLoS One 7: e34546, 2012.
17. Wu XS, Yang T, Gu J, Li ML, Wu WG, Weng H, Ding Q, Mu JS, Bao RF, Shu YJ, et al: Effects of oxymatrine on the apoptosis and proliferation of gallbladder cancer cells. Anticancer Drugs 25: 1005-1015, 2014.
18. Yang Z, Yin R, Cong Y, Yang Z, Zhou E, Wei Z, Liu Z, Cao Y and Zhang N: Oxymatrine lightened the infammatory response of LPS-induced mastitis in mice through affecting NF-κB and MAPKs signaling pathways. Infammation 37: 2047-2055, 2014.
19. Zhang Y, Piao B, Zhang Y, Hua B, Hou W, Xu W, Qi X, Zhu X, Pei Y and Lin H: Oxymatrine diminishes the side population and inhibits the expression of β-catenin in MCF-7 breast cancer cells. Med Oncol 28 (Suppl 1): S99-S107, 2011.
20. Zhang Y, Liu H, Jin J, Zhu X, Lu L and Jiang H: The role of endogenous reactive oxygen species in oxymatrine-induced caspase-3-dependent apoptosis in human melanoma A375 cells. Anticancer Drugs 21: 494-501, 2010.
21. Wu C, Huang W, Guo Y, et al: Oxymatrine inhibits the proliferation of prostate cancer cells in vitro and in vivo. Mol Med Rep 11: 4129-4134, 2015.
22. Chen H, Zhang J, Luo J, Lai F, Wang Z, Tong H, Lu D, Bu H, Zhang R and Lin S: Antiangiogenic effects of oxymatrine on pancreatic cancer by inhibition of the NF-κB-mediated VEGF signaling pathway. Oncol Rep 30: 589-595, 2013.
23. Ho JW, Ngan Hon PL and Chim WO: Effects of oxymatrine from Ku Shen on cancer cells. Anticancer Agents Med Chem 9: 823-826, 2009.
24. Dong XQ, Du Q, Yu WH, Zhang ZY, Zhu Q, Che ZH, Chen F, Wang H and Chen J: Anti-infammatory effects of oxymatrine through inhibition of nuclear factor-kappa B and mitogen-activated protein kinase activation in lipopolysaccharide-induced BV2 Microglia Cells. Iran J Pharm Res 12: 165-174, 2013.
25. Ling Q, Xu X, Wei X, Wang W, Zhou B, Wang B and Zheng S: Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c. J Exp Clin Cancer Res 30: 66, 2011.
26. Seo JM, Park S and Kim JH: Leukotriene B4 receptor-2 promotes invasiveness and metastasis of ovarian cancer cells through signal transducer and activator of transcription 3 (STAT3)-dependent up-regulation of matrix metalloproteinase 2. J Biol Chem 287: 13840-13849, 2012.
27. Li LQ, Li XL, Wang L, Du WJ, Guo R, Liang HH, Liu X, Liang DS, Lu YJ, Shan HL, et al: Matrine inhibits breast cancer growth via miR-21/PTEN/Akt pathway in MCF-7 cells. Cell Physiol Biochem 30: 631-641, 2012.
28. Zhang Y, Sun S, Chen J, Ren P, Hu Y, Cao Z, Sun H and Ding Y: Oxymatrine induces mitochondria dependent apoptosis in human osteosarcoma MNNG/HOS cells through inhibition of PI3K/Akt pathway. Tumour Biol 35: 1619-1625, 2014.
29. Gong J, Li J, Wang Y, Liu C, Jia H, Jiang C, Wang Y, Luo M, Zhao H, Dong L, et al: Characterization of microRNA-29 family expression and investigation of their mechanistic roles in gastric cancer. Carcinogenesis 35: 497-506, 2014.
30. Jiang H, Zhang G, Wu JH and Jiang CP: Diverse roles of miR-29 in cancer (review). Oncol Rep 31: 1509-1516, 2014.
31. Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA and Richer JK: Progestin suppression of miR-29 potentiates dedif-ferentiation of breast cancer cells via KLF4. Oncogene 32: 2555-2564, 2013.